ADIL - CIK 0001513525
ADIAL PHARMACEUTICALS, INC. (ADIL) reported net income of -$7.98M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$7.98M | +39.6% |
| FY 2024 | -$13.20M | -157.6% |
| FY 2023 | -$5.12M | +59.8% |
| FY 2022 | -$12.73M | +34.5% |
| FY 2021 | -$19.42M | -78.3% |
| FY 2020 | -$10.89M | -26.8% |
| FY 2019 | -$8.59M | +26.1% |
| FY 2018 | -$11.63M | -920.8% |
| FY 2017 |
ADIAL PHARMACEUTICALS, INC. (ADIL) reported net income of -$7.98M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, ADIAL PHARMACEUTICALS, INC.'s net income declined from -$1.14M to -$7.98M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$1.14M |
| - |